Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Pharmala Biotech Holdings Inc C.MDMA

Alternate Symbol(s):  MDXXF

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.


CSE:MDMA - Post by User

Comment by inviolablspiriton Apr 30, 2024 11:57am
83 Views
Post# 36014973

RE:Financials are out on Sedar

RE:Financials are out on SedarIf one wants to compare financial statements to similar company in the same sector go look at Opti.  Opti has roughly the same amount of shares outstanding and a minus $0.05 - $0.06 EPS and MDMA is  about $0.00 to minus $0.01 EPS.  MDMA's financial health is about 5x better than Opti's.  MDMA is running a more lean company and IMO has greater opportunities for success and profitability, yet Opti's share price is higher and their market cap is about $10 million more.   So either Opti's share price needs to come down or MDMA's share price needs to go up to reflect a more accurate price and financial statement between similar companies.   
<< Previous
Bullboard Posts
Next >>